Selection, identification, and characterization of SARS-CoV-2 monoclonal antibody resistant mutants.
Animals
Antibodies, Monoclonal
/ immunology
Antibodies, Neutralizing
/ immunology
Antigenic Variation
/ genetics
Binding Sites
/ genetics
COVID-19
/ virology
Chlorocebus aethiops
Drug Resistance, Viral
/ genetics
Humans
Phenotype
SARS-CoV-2
/ drug effects
Selection, Genetic
Spike Glycoprotein, Coronavirus
/ genetics
Vero Cells
COVID-19 Drug Treatment
COVID-19
Monoclonal antibodies
Monoclonal antibody resistant mutant
Neutralizing antibodies
RBD
SARS-CoV-2
Spike glycoprotein
Viral drift
Journal
Journal of virological methods
ISSN: 1879-0984
Titre abrégé: J Virol Methods
Pays: Netherlands
ID NLM: 8005839
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
28
10
2020
revised:
10
01
2021
accepted:
23
01
2021
pubmed:
30
1
2021
medline:
26
3
2021
entrez:
29
1
2021
Statut:
ppublish
Résumé
The use of monoclonal neutralizing antibodies (mNAbs) is being actively pursued as a viable intervention for the treatment of Severe Acute Respiratory Syndrome CoV-2 (SARS-CoV-2) infection and associated coronavirus disease 2019 (COVID-19). While highly potent mNAbs have great therapeutic potential, the ability of the virus to mutate and escape recognition and neutralization of mNAbs represents a potential problem in their use for the therapeutic management of SARS-CoV-2. Studies investigating natural or mNAb-induced antigenic variability in the receptor binding domain (RBD) of SARS-CoV-2 Spike (S) glycoprotein, and their effects on viral fitness are still rudimentary. In this manuscript we described experimental approaches for the selection, identification, and characterization of SARS-CoV-2 monoclonal antibody resistant mutants (MARMs) in cultured cells. The ability to study SARS-CoV-2 antigenic drift under selective immune pressure by mNAbs is important for the optimal implementation of mNAbs for the therapeutic management of COVID-19. This will help to identify essential amino acid residues in the viral S glycoprotein required for mNAb-mediated inhibition of viral infection, to predict potential natural drift variants that could emerge upon implementation of therapeutic mNAbs, as well as vaccine prophylactic treatments for SARS-CoV-2 infection. Additionally, it will also enable the assessment of MARM viral fitness and its potential to induce severe infection and associated COVID-19 disease.
Identifiants
pubmed: 33513380
pii: S0166-0934(21)00023-9
doi: 10.1016/j.jviromet.2021.114084
pmc: PMC7837211
pii:
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antibodies, Neutralizing
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
114084Subventions
Organisme : NIAID NIH HHS
ID : R01 AI145332
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI161175
Pays : United States
Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.
Références
Cell. 2020 Jul 9;182(1):73-84.e16
pubmed: 32425270
J Virol. 1993 Oct;67(10):6071-9
pubmed: 7690417
Science. 2020 Aug 7;369(6504):650-655
pubmed: 32571838
Nature. 2020 Aug;584(7821):450-456
pubmed: 32698192
Science. 2020 Aug 7;369(6504):731-736
pubmed: 32540900
Science. 2020 Aug 21;369(6506):1014-1018
pubmed: 32540904
Emerg Microbes Infect. 2020 Dec;9(1):837-842
pubmed: 32301390
Science. 2020 Aug 7;369(6504):643-650
pubmed: 32540902
Viruses. 2020 May 06;12(5):
pubmed: 32384820
J Pathol. 2020 Jul;251(3):228-248
pubmed: 32418199
Cell. 2020 Sep 17;182(6):1663-1673
pubmed: 32946786
J Virol Methods. 2021 Jan;287:113995
pubmed: 33068703
Science. 2020 Aug 21;369(6506):1010-1014
pubmed: 32540901
BMC Microbiol. 2006 Oct 04;6:88
pubmed: 17020602
Nature. 2020 Aug;584(7821):437-442
pubmed: 32555388
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Elife. 2020 Oct 28;9:
pubmed: 33112236
Infect Genet Evol. 2020 Jul;81:104260
pubmed: 32092483
Curr Protoc Microbiol. 2020 Sep;58(1):e108
pubmed: 32585083
Nature. 2020 Aug;584(7819):120-124
pubmed: 32454512
Curr Protoc Microbiol. 2020 Dec;59(1):e126
pubmed: 33048448
Nature. 2020 Dec;588(7839):E35
pubmed: 33303961
Nat Commun. 2020 May 4;11(1):2251
pubmed: 32366817
J Virol. 2008 Feb;82(4):1688-700
pubmed: 18057242
Cell. 2020 Aug 20;182(4):812-827.e19
pubmed: 32697968
Proc Natl Acad Sci U S A. 2020 Mar 31;117(13):7001-7003
pubmed: 32165541
Nat Commun. 2020 Nov 30;11(1):6122
pubmed: 33257679
Cell Rep Med. 2021 Mar 16;2(3):100218
pubmed: 33649747
J Virol. 2020 Mar 17;94(7):
pubmed: 31996437
mBio. 2020 Sep 25;11(5):
pubmed: 32978313
Nature. 2020 Aug;584(7819):115-119
pubmed: 32454513
J Biol Chem. 2020 Oct 9;295(41):13958-13964
pubmed: 32587093
Science. 2020 Aug 21;369(6506):956-963
pubmed: 32540903
Cell Mol Immunol. 2020 Jun;17(6):647-649
pubmed: 32313207
Clin Vaccine Immunol. 2010 Jul;17(7):1055-65
pubmed: 20463105
Cell. 2020 Sep 3;182(5):1284-1294.e9
pubmed: 32730807
J Virol. 2012 Sep;86(17):9113-21
pubmed: 22696652
Immunity. 2020 Jul 14;53(1):98-105.e5
pubmed: 32561270